Advertisement

HNO

pp 1–15 | Cite as

Immunonkologie von Kopf-Hals-Tumoren

  • Stefan KasperEmail author
  • Timon Hussain
  • Isabel Virchow
  • Martin Stuschke
  • Stephan Lang
CME
  • 66 Downloads

Zusammenfassung

Die Behandlung von Patienten mit Plattenepithelkarzinomen des Kopf-Hals-Bereichs ist multimodal unter Einschluss modernster operativer, strahlentherapeutischer sowie medikamentöser Verfahren. Dennoch bleibt die Prognose über alle Stadien unbefriedigend. Bei einem Rezidiv oder einer Metastasierung nach definitiver Therapie besteht die Indikation zur systemischen palliativen Therapie, wobei sich neben der klassischen platinbasierten Chemotherapie und Cetuximab, einem Antikörper gegen den epidermalen Wachstumsfaktorrezeptor („epidermal growth factor receptor“, EGFR), in den letzten Jahren die immunonkologische (IO-)Therapie erfolgreich etabliert hat. Für die Zulassung von „Checkpointinhibitoren“ in der palliativen Situation nach Platinversagen relevante Studienergebnisse sowie derzeit laufende Studien zu deren Stellenwert in Erstlinientherapie, Kombination mit definitiver oder adjuvanter Bestrahlung, präoperativ beim resektablen Kopf-Hals-Tumor sowie in IO-Kombinationstherapie werden erörtert.

Schlüsselwörter

Plattenepithelkarzinom Kopf-Hals-Neoplasien Antineoplastische kombinierte Chemotherapieprotokolle Radiotherapie, adjuvante Radiochemotherapie 

Immuno-oncology of head and neck tumors

Abstract

Treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) is nowadays multidisciplinary. Therapeutic concepts include modern surgical and radiation techniques as well as systemic therapies. However, the prognosis of these patients is still poor for all stages. In the recurrent or metastatic situation after definitive therapy, there is an indication for palliative systemic treatment, whereby classical platinum-based chemotherapy and the monoclonal epidermal growth factor receptor (EGFR) antibody cetuximab are established, and immunotherapy (IO) has recently been proven a potent treatment option. In this review, the results of trials relevant for approval of checkpoint inhibitors in the palliative setting after platinum failure, as well as ongoing trials evaluating their impact as first-line treatment, in combination with definitive or adjuvant radiation, preoperatively in resectable head and neck cancers, or in combination with other IO therapeutics shall be discussed.

Keywords

Squamous cell carcinoma Head and neck neoplasms Antineoplastic combined chemotherapy protocols Radiotherapy, adjuvant Chemoradiotherapy 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

S. Kasper gibt an: Beratung und Vorträge für BMS, MSD, AstraZeneca, Roche und Merck; Unterstützung für wissenschaftliche Forschung von BMS, Roche und Merck; andere finanzielle Unterstützung von BMS, Roche, MSD, AstraZeneca und Merck. T. Hussain, I. Virchow, M. Stuschke und S. Lang geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
  2. 2.
  3. 3.
    Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214–218CrossRefGoogle Scholar
  4. 4.
    Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127.  https://doi.org/10.1056/NEJMoa0802656 CrossRefPubMedGoogle Scholar
  5. 5.
    Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838–3845CrossRefGoogle Scholar
  6. 6.
    Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17:956–965CrossRefGoogle Scholar
  7. 7.
    Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R (2017) Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol 35:1542–1549CrossRefGoogle Scholar
  8. 8.
    Siu L, Even C, Mesía R, Daste A, Krauss J, Saba NF, Nabell L, Ready NE, Brana Garcia I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Jarkowski A, Melillo G, Armstrong JM, Fayette J (2018) A randomized, open-label, multicenter, global phase 2 study of Durvalumab (D), Tremelimumab (T), or D plus T, in patients with PD-L1 low/negative recurrent or metastatic head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 100:1083–1408CrossRefGoogle Scholar
  9. 9.
    Zandberg D, Algazi A, Jimeno A, Godd JS, Fayette J, Bouganim N, Ready N, Clement PM, Goswmi T, Jarkowski A, Armstrong JM, Asubonteng K, Melillo G, Mesia R (2017) Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study. Ann Oncol 28(suppl_5):v372–v394CrossRefGoogle Scholar
  10. 10.
    Bahleda R, Braiteh FS, Balmanoukian AS, Braña I, Hodi FS, Garbo L, Liu B, Molinero L, O’Hear C, Shen X, Fasso M, Colevas AD (2017) Long-term safety and clinical outcomes of atezolizumab in head and neck cancer: phase Ia trial results. Ann Oncol 28(suppl_5):v372–v394CrossRefGoogle Scholar
  11. 11.
    Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867CrossRefGoogle Scholar
  12. 12.
    Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Kopit J, Ferris RL (2017) Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy. J Clin Oncol 35:abstr 6019CrossRefGoogle Scholar
  13. 13.
    Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J (2017) Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 18:1104–1115CrossRefGoogle Scholar
  14. 14.
    Cohen EE, Harrington KJ, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Wang Y, Tuozzo AJ, Swaby R, Soulieres D (2017) Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial. Ann Oncol 28(suppl_5):v605-v649Google Scholar
  15. 15.
    Ferris RL, Even C, Haddad R, Tahara M, Goswami T, Franks A, Emeribe U, Jarkoski A, Melillo G, Licitra L (2015) Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle. J Immunother Cancer 3:P150CrossRefGoogle Scholar
  16. 16.
    Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420CrossRefGoogle Scholar
  17. 17.
    Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG (2017) RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143–e152CrossRefGoogle Scholar
  18. 18.
    Pignon JP, le Maître A, Maillard E, Bourhis J (2009) MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefGoogle Scholar
  19. 19.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578CrossRefGoogle Scholar
  20. 20.
    Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28CrossRefGoogle Scholar
  21. 21.
    Gillison M, Ferris RL, Zhang Q, Colevas AD, Mell LK, Kirsch C, Moore KL, Truong MT, Kong CS, Jordan R, Clump DA, Ohr J, He K, Blakaj D, Deeken J, Machtay M, Curran WJ Jr, Harris J, Le QT (2018) Safety evaluation of nivolumab (Nivo) concomitant with platinum-based chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local- regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504. Int J Radiat Oncol Biol Phys 100:p1083–1408CrossRefGoogle Scholar
  22. 22.
    Powell SF, Gitau MM, Sumey CJ, Reynolds JT, Lohr M, McGraw S, Nowak RK, Terrell AM, Jensen AW, Blanchard MJ, Ellison C, Black LJ, Thompson PA, Gold KA, Cohen EE, Lee JH, Spanos WC (2017) Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). J Clin Oncol 35(15_suppl):6011–6011CrossRefGoogle Scholar
  23. 23.
    Ferris RL, Gillison ML, Harris J, Colevas AD, Mell LK, Kong C, Jordan R, Moore K, Truong MT, Kirsch C, Clump DA, Ohr J, He K, Blakaj D, Deeken JF, Machtay M, Curran WJ, Le QT (2018) Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504. J Clin Oncol 36:abstr 6010CrossRefGoogle Scholar
  24. 24.
    Sun XS, Sire C, Tao Y, Martin L, Alfonsi M, Prevost JB, Rives M, Lafond C, Tourani JM, Biau J, Geoffrois L, Coutte A, Liem X, Vauleon E, Drouet F, Ramee JF, Waksi G, Sinigaglia L, Auperin A, Bourhis J (2018) A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial. J Clin Oncol 36:abstr 6018CrossRefGoogle Scholar
  25. 25.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Stefan Kasper
    • 1
    Email author
  • Timon Hussain
    • 2
  • Isabel Virchow
    • 1
  • Martin Stuschke
    • 3
  • Stephan Lang
    • 2
  1. 1.Westdeutsches Tumorzentrum, Innere Klinik (Tumorforschung)Universitätsklinikum EssenEssenDeutschland
  2. 2.Westdeutsches Tumorzentrum, Klinik für Hals‑, Nasen- und OhrenheilkundeUniversitätsklinikum EssenEssenDeutschland
  3. 3.Westdeutsches Tumorzentrum, Klinik für StrahlentherapieUniversitätsklinikum EssenEssenDeutschland

Personalised recommendations